J Cell Biochem:外泌体circ_0044516能够促进前列腺癌细胞增殖和转移

2019-10-30 Alex Yang MedSci原创

环状RNA(circRNAs)是癌症生长和恶化的重要调控因子。外泌体携带各种各样分子,包括RNA、蛋白和从一个细胞到另一个细胞的脂质。但是来自前列腺癌患者的外泌体circRNAs的作用仍旧不清楚。最近,有研究人员发现circ_0044516在前列腺癌中表达上调,并调查了Hsa_circ_0044516 (circ_0044516)的分子机制。首先,研究人员从前列腺癌患者中收集了外泌体,并进行人类c

环状RNA(circRNAs)是癌症生长和恶化的重要调控因子。外泌体携带各种各样分子,包括RNA、蛋白和从一个细胞到另一个细胞的脂质。但是来自前列腺癌患者的外泌体circRNAs的作用仍旧不清楚。

最近,有研究人员发现circ_0044516在前列腺癌中表达上调,并调查了Hsa_circ_0044516 (circ_0044516)的分子机制。首先,研究人员从前列腺癌患者中收集了外泌体,并进行人类circRNAs芯片分析来调查circRNA的表达情况。研究发现,共有35个显著过表达的circRNAs,其表达量增加不少于5倍。Circ_0044516在前列腺癌患者和细胞系中外泌体中显著上调。进一步的调查阐释了circ_0044516表达的下调能够抑制前列腺癌细胞的增殖和转移。通过生物信息学分析和双荧光素酶报告分析,circ_0044516能够下调miR-29a-3p的表达且与miR-29a-3p的表达水平呈现负相关关系。

最后,研究人员指出,他们的研究表明了circ_0044516在前列腺癌细胞的生存和转移中具有重要的作用,表面了circ_0044516在前列腺癌中是具有致瘤角色的。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=902378, encodeId=53929023e8a7, content=很有用处!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ecc5435306, createdName=ms5000000427104193, createdTime=Thu Nov 26 08:41:19 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918894, encodeId=36c21918894f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 17 03:02:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961752, encodeId=06de1961e5294, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 10 20:02:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871465, encodeId=f11f18e14658d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 30 11:02:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701037, encodeId=4f591e0103719, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Tue Nov 19 09:02:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252654, encodeId=5c02125265487, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540949, encodeId=3f46154094964, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620262, encodeId=33ab162026206, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374649, encodeId=beb13e46492e, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Thu Oct 31 20:35:47 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040579, encodeId=bd0110405e915, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Oct 31 00:02:00 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
    2020-11-26 ms5000000427104193

    很有用处!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=902378, encodeId=53929023e8a7, content=很有用处!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ecc5435306, createdName=ms5000000427104193, createdTime=Thu Nov 26 08:41:19 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918894, encodeId=36c21918894f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 17 03:02:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961752, encodeId=06de1961e5294, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 10 20:02:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871465, encodeId=f11f18e14658d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 30 11:02:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701037, encodeId=4f591e0103719, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Tue Nov 19 09:02:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252654, encodeId=5c02125265487, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540949, encodeId=3f46154094964, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620262, encodeId=33ab162026206, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374649, encodeId=beb13e46492e, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Thu Oct 31 20:35:47 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040579, encodeId=bd0110405e915, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Oct 31 00:02:00 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
    2020-03-17 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=902378, encodeId=53929023e8a7, content=很有用处!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ecc5435306, createdName=ms5000000427104193, createdTime=Thu Nov 26 08:41:19 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918894, encodeId=36c21918894f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 17 03:02:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961752, encodeId=06de1961e5294, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 10 20:02:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871465, encodeId=f11f18e14658d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 30 11:02:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701037, encodeId=4f591e0103719, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Tue Nov 19 09:02:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252654, encodeId=5c02125265487, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540949, encodeId=3f46154094964, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620262, encodeId=33ab162026206, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374649, encodeId=beb13e46492e, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Thu Oct 31 20:35:47 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040579, encodeId=bd0110405e915, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Oct 31 00:02:00 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
    2020-01-10 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=902378, encodeId=53929023e8a7, content=很有用处!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ecc5435306, createdName=ms5000000427104193, createdTime=Thu Nov 26 08:41:19 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918894, encodeId=36c21918894f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 17 03:02:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961752, encodeId=06de1961e5294, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 10 20:02:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871465, encodeId=f11f18e14658d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 30 11:02:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701037, encodeId=4f591e0103719, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Tue Nov 19 09:02:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252654, encodeId=5c02125265487, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540949, encodeId=3f46154094964, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620262, encodeId=33ab162026206, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374649, encodeId=beb13e46492e, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Thu Oct 31 20:35:47 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040579, encodeId=bd0110405e915, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Oct 31 00:02:00 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=902378, encodeId=53929023e8a7, content=很有用处!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ecc5435306, createdName=ms5000000427104193, createdTime=Thu Nov 26 08:41:19 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918894, encodeId=36c21918894f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 17 03:02:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961752, encodeId=06de1961e5294, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 10 20:02:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871465, encodeId=f11f18e14658d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 30 11:02:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701037, encodeId=4f591e0103719, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Tue Nov 19 09:02:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252654, encodeId=5c02125265487, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540949, encodeId=3f46154094964, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620262, encodeId=33ab162026206, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374649, encodeId=beb13e46492e, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Thu Oct 31 20:35:47 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040579, encodeId=bd0110405e915, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Oct 31 00:02:00 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=902378, encodeId=53929023e8a7, content=很有用处!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ecc5435306, createdName=ms5000000427104193, createdTime=Thu Nov 26 08:41:19 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918894, encodeId=36c21918894f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 17 03:02:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961752, encodeId=06de1961e5294, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 10 20:02:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871465, encodeId=f11f18e14658d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 30 11:02:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701037, encodeId=4f591e0103719, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Tue Nov 19 09:02:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252654, encodeId=5c02125265487, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540949, encodeId=3f46154094964, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620262, encodeId=33ab162026206, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374649, encodeId=beb13e46492e, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Thu Oct 31 20:35:47 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040579, encodeId=bd0110405e915, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Oct 31 00:02:00 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
    2019-11-01 yxch36
  7. [GetPortalCommentsPageByObjectIdResponse(id=902378, encodeId=53929023e8a7, content=很有用处!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ecc5435306, createdName=ms5000000427104193, createdTime=Thu Nov 26 08:41:19 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918894, encodeId=36c21918894f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 17 03:02:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961752, encodeId=06de1961e5294, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 10 20:02:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871465, encodeId=f11f18e14658d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 30 11:02:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701037, encodeId=4f591e0103719, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Tue Nov 19 09:02:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252654, encodeId=5c02125265487, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540949, encodeId=3f46154094964, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620262, encodeId=33ab162026206, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374649, encodeId=beb13e46492e, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Thu Oct 31 20:35:47 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040579, encodeId=bd0110405e915, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Oct 31 00:02:00 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=902378, encodeId=53929023e8a7, content=很有用处!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ecc5435306, createdName=ms5000000427104193, createdTime=Thu Nov 26 08:41:19 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918894, encodeId=36c21918894f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 17 03:02:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961752, encodeId=06de1961e5294, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 10 20:02:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871465, encodeId=f11f18e14658d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 30 11:02:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701037, encodeId=4f591e0103719, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Tue Nov 19 09:02:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252654, encodeId=5c02125265487, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540949, encodeId=3f46154094964, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620262, encodeId=33ab162026206, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374649, encodeId=beb13e46492e, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Thu Oct 31 20:35:47 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040579, encodeId=bd0110405e915, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Oct 31 00:02:00 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=902378, encodeId=53929023e8a7, content=很有用处!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ecc5435306, createdName=ms5000000427104193, createdTime=Thu Nov 26 08:41:19 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918894, encodeId=36c21918894f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 17 03:02:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961752, encodeId=06de1961e5294, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 10 20:02:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871465, encodeId=f11f18e14658d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 30 11:02:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701037, encodeId=4f591e0103719, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Tue Nov 19 09:02:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252654, encodeId=5c02125265487, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540949, encodeId=3f46154094964, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620262, encodeId=33ab162026206, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374649, encodeId=beb13e46492e, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Thu Oct 31 20:35:47 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040579, encodeId=bd0110405e915, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Oct 31 00:02:00 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
    2019-10-31 njwbhuang

    学习了!

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=902378, encodeId=53929023e8a7, content=很有用处!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ecc5435306, createdName=ms5000000427104193, createdTime=Thu Nov 26 08:41:19 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918894, encodeId=36c21918894f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Mar 17 03:02:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961752, encodeId=06de1961e5294, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 10 20:02:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871465, encodeId=f11f18e14658d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 30 11:02:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701037, encodeId=4f591e0103719, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Tue Nov 19 09:02:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252654, encodeId=5c02125265487, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540949, encodeId=3f46154094964, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620262, encodeId=33ab162026206, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Nov 01 12:02:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374649, encodeId=beb13e46492e, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Thu Oct 31 20:35:47 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040579, encodeId=bd0110405e915, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Oct 31 00:02:00 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
    2019-10-31 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

盘点:前列腺癌相关机制

【1】Cell Death & Disease:信号转换和转录激活子3能够促使高脂肪饮食相关的前列腺癌的生长 https://www.nature.com/articles/s41419-019-1842-4前列腺癌(PCa)是男性的第二大致死性癌症。PCa的恶化与肥胖相关。信号转换和转录激活子3(STAT3)在PCa生长过程中具有关键的作用。然而,是否STAT3在高脂肪饮食(HFD)

Lancet oncol:短期雄激素剥夺疗法联合放疗作为前列腺癌术后的补救治疗

放疗是根治性前列腺切除术后的标准补救疗法。迄今为止,雄激素剥夺疗法的作用尚未被正式证明。在本研究中,研究人员汇报了GETUG-AFU 16试验的随访结果。GETUG-AFU 16试验是一个开放性的多中心3期随机对照试验,招募年满18岁的ECOG表现状态0或1分的组织学确诊的pT2、T3或T4a和pN0或pNx期的前列腺腺癌患者。将受试者随机分至短疗程雄激素抑制(放疗第一天和3个月后皮下注射10.8

Urol Oncol:局部前列腺癌治疗高强度聚焦超声(HIFU)治疗的前瞻性多中心研究

最近,有研究人员为了调查高强度聚焦超声(HIFU)的重点疗法在局部前列腺癌(CaP)治疗中的情况,分析了上述疗法的安全性和并发症情况。研究包括了2个欧洲中心的98名男性,其中35名患者(35.7%)在HIFU干预后前30天经历了副作用事件(AEs),且Clavien-Dindo分级≤II。15名患者(15.3%)出现了术后泌尿系感染,26名患者(26.5%)出现尿滞留情况。4名患者(4.1%)经历

Plos Med:一个神奇的临床试验:不是免疫治疗,不是靶向治疗,却极受病人欢迎

丹麦科学家最近发表了一项研究结果,是一项在前列腺癌患者中进行的随机对照临床试验。

Prostate Cancer P D:美国退伍军人前列腺癌患者中的抽烟与死亡率关系研究

抽烟是一些泌尿生殖系统癌症死亡的一个风险因子,很可能是致癌物质在尿液中的积累导致。然而,在前列腺癌中抽烟与死亡率的关系还很少研究。最近,有研究人员评估了诊断为PC的抽烟者、有抽烟历史者和从不抽烟者中前列腺癌特异性死亡率(PCSM)的差异。研究是一个回顾性的群体研究,包括了73668名男性(抽烟者:22608名(30.7%)、有抽烟历史者:23695(32.1%)和从不抽烟者:27365(37.1%

Prostate Cancer P D:派姆单抗加前列腺冷冻疗法治疗新诊断低转移激素敏感性前列腺癌的初步研究

免疫检查点抑制剂的单一疗法在男性晚期前列腺癌治疗中普遍不成功。预临床数据表明了冷冻疗法可能能够改善免疫调控和抗肿瘤响应。最近,有研究人员评估了全前列腺腺体冷冻治疗结合派姆单抗和激素阻断治疗在低转移激素敏感性前列腺癌中的安全性和可行性情况。研究是一个单中心的初步试验,招募了12名新诊断为低转移激素敏感性前列腺癌患者,时间为2105年和2016年之间。这些患者进行全前列腺腺体冷冻治疗结合短期激素阻断治